Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)
Portfolio Pulse from Benzinga Insights
Ionis Pharmaceuticals (NASDAQ:IONS) has received mixed analyst ratings, with a recent average price target of $61.08, reflecting a 10.89% increase from the previous target. Analysts have varied in their ratings, with some raising their price targets and others maintaining or lowering them. Ionis is a leader in antisense technology, with a focus on cardiovascular, metabolic, neurological, and rare diseases. Despite positive revenue growth, the company faces challenges with below-average ROE and ROA, and a high debt-to-equity ratio.
September 26, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ionis Pharmaceuticals has received a mix of bullish and bearish analyst ratings, with a recent average price target of $61.08, up 10.89% from the previous target. Analysts have varied in their ratings, with some raising their price targets and others maintaining or lowering them. Ionis is a leader in antisense technology, focusing on cardiovascular, metabolic, neurological, and rare diseases. Despite positive revenue growth, the company faces challenges with below-average ROE and ROA, and a high debt-to-equity ratio.
The mixed analyst ratings and increased average price target suggest a neutral short-term impact on Ionis Pharmaceuticals' stock. While the company shows positive revenue growth, its financial metrics like ROE, ROA, and debt levels indicate potential challenges. The varied analyst ratings reflect differing opinions on the company's future performance, leading to a neutral short-term outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100